1. Academic Validation
  2. Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade

Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade

  • Acta Biomater. 2025 Mar 1:194:305-322. doi: 10.1016/j.actbio.2025.01.015.
Meixu Chen 1 Linlin Song 2 Yao Zhou 1 Tianyue Xu 1 Ting Sun 3 Zhihui Liu 1 Zihan Xu 1 Yujie Zhao 1 Peixin Du 1 Yingying Ma 1 Liwen Huang 1 Xiaoting Chen 4 Guang Yang 4 Jing Jing 5 Hubing Shi 6
Affiliations

Affiliations

  • 1 Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, China.
  • 2 Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, China; Department of Ultrasound & Laboratory of Ultrasound Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • 3 Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, China; Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • 4 Animal Experimental Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • 5 Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, China. Electronic address: [email protected].
  • 6 Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, 610041, China. Electronic address: [email protected].
Abstract

Although immunotherapy has revolutionized clinical Cancer treatment, the efficacy is limited due to the lack of tumor-associated antigens (TAAs) and the presence of compensatory immune checkpoints. To overcome the deficiency, a nano-system loaded with ozone and CD47 Inhibitor RRx-001 is designed and synthesized. Upon irradiation, Reactive Oxygen Species (ROS) generated from ozone reacts with nitric oxide (NO) metabolized from RRx-001 to form reactive nitrogen species (RNS), which presents a much stronger cell-killing ability than ROS. Molecular mechanism studies further reveal that RNS induce extensive immunogenic cell death (ICD). The released TAAs promote infiltration of cytotoxic T lymphocytes, which provides the basis for immune checkpoint blockade (ICB) therapy. Meanwhile, RRx-001 carried by the nanoparticles and the produced radicals repolarize M2-type tumor-associated macrophages (TAMs) into the anti-tumor M1-type, consequently reversing the immunosuppressive tumor microenvironment (TME). In a xenograft triple-negative breast Cancer (TNBC) animal model, O3-001@lipo (Liposome enwrapping O3 and RRx-001) plus irradiation shows a significant anti-tumor efficacy by improving cytotoxic lymphocyte infiltration and regulating immunosuppressive TME. In summary, the O3-001@lipo nano-system triggered by irradiation potently improves the efficacy of immunotherapy by introducing strong cytotoxic RNS, which not only enriches the toolbox of ICD inducer but also provides a strategy of treatment for immune deficient tumor. STATEMENT OF SIGNIFICANCE: This study introduces a nano-system that leverages ozone and RRx-001 in the presence of X-ray irradiation to generate reactive nitrogen species, enhancing immunogenic cell death and promoting T-lymphocyte infiltration in triple-negative breast Cancer, addressing a significant unmet need in the field. The scientific contribution is the development of a clinically translatable nano-system that not only induces ICD but also reshapes the tumor microenvironment, which is expected to have a profound impact on the readership in pharmaceutics, material science, and nano-bio interaction, particularly for those interested in advanced immune therapy approaches.

Keywords

Controlled-release system; Immune checkpoint blockade; Ozone; Reactive nitrogen species; Triple-negative breast cancer.

Figures
Products